Explore the words cloud of the BRIGHT project. It provides you a very rough idea of what is the project "BRIGHT" about.
The following table provides information about the project.
|Coordinator Country||Denmark [DK]|
|Total cost||71˙429 €|
|EC max contribution||50˙000 € (70%)|
1. H2020-EU.3. (PRIORITY 'Societal challenges)
2. H2020-EU.2.3. (INDUSTRIAL LEADERSHIP - Innovation In SMEs)
3. H2020-EU.2.1. (INDUSTRIAL LEADERSHIP - Leadership in enabling and industrial technologies)
|Duration (year-month-day)||from 2019-05-01 to 2019-09-30|
Take a look of project's partnership.
|1||OPTOCEUTICS APS||DK (KONGENS LYNGBY)||coordinator||50˙000.00|
While Alzheimer’s Disease (AD) is a global pandemic, it has been estimated that a five-year delay in the disease onset could reduce the disease prevalence – and its costs – by up to 33% over the next decades, representing potential savings over €100bn in EU alone. However, there are still significant roadblocks ahead as current drugs do not untap sizeable improvements in AD patients. This is primarily due to the challenge of minimizing the impact of irreversible brain damage in later dementia stages, which accentuates the need for early intervention. However, recent evidence shows that non-invasive flashing (stroboscopic) light at the appropriate frequency (40 Hz) promotes clearance of beta-amyloid – whose accumulation is believe to be one of the key triggers to the neurodegenerative cascade leading to dementia states.
Instead of using fadigue-inducing stroboscopic flashing light (i.e. on-off), the founding members of OptoCeutics have devised a unique, patent-protected method to stimulate the human visual receptors and processing cortex through alternating white light composed of different wavelengths. The two variants of the white light are formed by different combinations of coloured LEDs. When flickering between the two LED sets, the colours fusion together and appear as one, resulting in approximately the same white colour, avoiding experiencing light flashing, but the brain is capturing the blue component flashing with 40 Hz – thus still promoting neuro-protective beta-amyloid clearance.
OptoCeutics will leverage from BRIGHT as a vital stepping stone to prepare the company’s business strategy, serving also to significantly de-risk its route-to-market by enabling to liaise with major industrial and clinical players to define both the optimal productization and maturation of Optoceutics core technology, as well as the setup for its full-scale demonstration and certification, prior market roll-out.
Are you the coordinator (or a participant) of this project? Plaese send me more information about the "BRIGHT" project.
For instance: the website url (it has not provided by EU-opendata yet), the logo, a more detailed description of the project (in plain text as a rtf file or a word file), some pictures (as picture files, not embedded into any word file), twitter account, linkedin page, etc.
Send me an email (firstname.lastname@example.org) and I put them in your project's page as son as possible.
Thanks. And then put a link of this page into your project's website.
The information about "BRIGHT" are provided by the European Opendata Portal: CORDIS opendata.
CathVision Cube: disruptive data-driven guidance for successful cardiac ablation therapyRead More
Wearable technology for the selective detection and continuous monitoring of movement disorders related to Parkinson’s diseaseRead More
AUTOMATED DIAGNOSTICS AND RADIOLOGICAL READING FROM LUMBAR SPINE MRIRead More